Efficacy of memantine in patients with moderate-to-severe Alzheimer's disease: results of pooled analysis, using realistic definitions of response, of two randomized, double-blind, placebo-controlled trials in Japan

Trial Profile

Efficacy of memantine in patients with moderate-to-severe Alzheimer's disease: results of pooled analysis, using realistic definitions of response, of two randomized, double-blind, placebo-controlled trials in Japan

Completed
Phase of Trial: Phase III

Latest Information Update: 17 Aug 2017

At a glance

  • Drugs Memantine (Primary)
  • Indications Alzheimer's disease
  • Focus Therapeutic Use
  • Sponsors Daiichi Sankyo Company
  • Most Recent Events

    • 15 Aug 2017 Status changed from not yet recruiting to completed.
    • 15 Feb 2017 New trial record
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top